GSK-3 and BCL-XL inhibition mitigates the competitive advantage of APC-mutant colorectal cancer cells

GSK-3 and BCL-XL inhibition mitigates the competitive advantage of APC-mutant colorectal cancer cells

Abstract BCL-XL is a crucial anti-apoptotic protein that supports survival of intestinal cells during the progression and in established colorectal cancer (CRC). While targeting BCL-XL with BH3 mimetics is effective, its significant toxicity highlights the need for alternative approaches. Importantl...

Full description

Saved in:
Bibliographic Details
Main Authors: Le Zhang, Lidia Atencia Taboada, Selami Baglamis, Maartje de Kroon, Carolien Elshout, Prashanthi Ramesh, Roxan F.C.P.A Helderman, Arezo Torang, Kate Cameron, Milou S. van Driel, Valérie M. Wouters, Sanne M. van Neerven, Jan Paul Medema
Format: Article
Language:English
Published: Nature Publishing Group 2025-07-01
Series:Oncogenesis
Online Access:https://doi.org/10.1038/s41389-025-00569-y
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items